Journals / Anestezi Dergisi / 2000 / Cilt: 8 - Sayı: 1

The cardioprotective effects of diltiazem during hypothermic cardiopulmonary bypass

Diltiazemin hipotermik kardiyopulmoner bypass esnasında kardiyoprotektif etkinliği

Pages
10–14
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

It has been concluded that diltiazem did not prevent lipid peroxidat ion but protected the myocardium under hypothermic conditions by other postulated mechanisms.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:In our study, we aimed to investigate the myocardial protective and antiperoxidant effects of diltiazem infusion given during cardiopulmonary bypass (CPB) in addition to cold blood cardioplegia in 20 patients undergoing coronary artery bypass grafting surgery.
📊
Key Findings & Data:In diltiazem group (group D) 0.3 mg kg-1 iv diltiazem was given after induction and infused at 2 mg.kg-1 min-1 until declamping the aorta.
💡
Conclusion & Impact:It has been concluded that diltiazem did not prevent lipid peroxidat ion but protected the myocardium under hypothermic conditions by other postulated mechanisms.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Kalsiyum kanal blokörleri · Miyokardiyal reperfüzyon hasarı · Diltiazem

Abstract

In our study, we aimed to investigate the myocardial protective and antiperoxidant effects of diltiazem infusion given during cardiopulmonary bypass (CPB) in addition to cold blood cardioplegia in 20 patients undergoing coronary artery bypass grafting surgery. In diltiazem group (group D) 0.3 mg kg-1 iv diltiazem was given after induction and infused at 2 mg.kg-1 min-1 until declamping the aorta. Group C was the control group. After declamping, the arterial and coronary sinus malondialdehyde levels, measured as a marker of lipid peroxidation incresed significantly in both groups when compared with the basal values and there was no difference between the preoperative levels but there was no significant difference between the groups. Hemodynamic measurement after CPB revealed significant increase in CI and LVSWI in group D with respect to group C. Ventricular fibrillation was observed in 1 patient in group D and 6 patients in group C (p<0.05). It has been concluded that diltiazem did not prevent lipid peroxidat ion but protected the myocardium under hypothermic conditions by other postulated mechanisms.

Özet

Koroner arter bypass greft (KABG) cerrahisi uygulanan 20 hasta üzerinde gerçekleştirilen çalışmamızda soğuk kan kardiyoplejisine ek olarak uygulanan diltiazem infüzyonunun miyokardı koruyucu etkinliginin ve antiperoksidan etkisinin araştırılması amaçlandı. Diltiazem grubunda (D grubu) indüksiyon sonrasında 0.3 mg/kg iv diltiazem uygulandı ve X-klemp kaldırılıncaya kadar 2 mg/kg/dk dozunda infüze edildi. K grubu kontrol grubu olarak izlendi. X-klemp kaldırıldığında, lipid peroksidasyonun bir ürünü olan malondialdehit (MDA) düzeyleri her iki grupta da bazal değerlere göre anlamlı yüksek bulundu ve iki grup arasında fark belirlenmedi. CPK, CK-MB ve LDH düzeyleri postoperatif 2. saatte her iki grupta da preoperatif düzeylere göre anlamlı artış gösterdi ve gruplar arasında anlamlı fark gözlenmedi. Hemodinamik ölçümlerde kardiyopulmoner bypass (KPB) sonrasında CI ve LSVWI, D grubunda K grubuna göre anlamlı yüksek bulundu. X-klemp kaldırıldığında D grubunda 6 hastada ventriküler fibrilasyon (VF) gözlendi (p<0.05). Çalışmamızın sonucunda diltiazemin lipid peroksidasyonunu engellemediği ve başka etki mekanizmalarıyla hiportermik koşullarda da kardiyoprotektif etkisi olduğu kanısına varıldı.

🔖

Cite This Article

AŞKAR, F. Z., DEMİRAĞ, K., UYAR, M., ÇEVİK, A. (2000). The cardioprotective effects of diltiazem during hypothermic cardiopulmonary bypass. Anestezi Dergisi, Cilt: 8 - Sayı: 1, 10–14. https://ajindex.com/articles/355406

References (14)

  1. Lell WA. Myocardial protection during cardipulmonary bypass. In: Kaplan JE (eds) Cardiac Anesthesia. Philadelphia, WB Saunders Company 1993; 1030-1057
  2. Hearse DJ. Stunning: A radical review. In: Opie LH (eds) Stunning, hipernation and calcium in myocardial ischaemia and reperfusion, Boston, Kluwer Academic Publishers 1992: 10-55
  3. Chan WP, Bharadwaj B, Prasad K. Effects of diltiazem on the functional recovery of the myocardium at organ and cellular level during prolonged hypothermic ischernic cardiac arrest. Angiology 1990:702-14
  4. Villan B. Ambrosio G, Golino P, et al. The effects of calcium channel antagonist treatment and oxygen radical scavenging on infarct size and the no-reflow phenomenon in reperfused hearts. Am Heart J 1993; 125: 11-23
  5. Tanguay M, Lepage G, Blasia G, Garceau D, Dumont L. Clantiazem, diltiazem and cold cardioplegia in isolated ischemic rabbit hearts: Relation between additive cardioprotection. physicochemical properties and preservation of myocardial lipid components. J Cardiovasc Pharmacol 1994; 24; 950-9
  6. Abdelmeguid AE, Feher JJ. Effects of low perfusate [Ca+2] and diltiazem on sareoplasmic reticuium in myocardial stuning. Am J Physiol 1994; 35: H 406-14
  7. Melendez FJ, Gharagozloo F, Sun SC. et al. Effects of diltiazem cardioplegia on global function, segmental contractility and the area of necrosis after acute coronary artery occlusion and surgical reperfusion. J Thorac Cardiovasc Surg 1988; 95: 613-7
  8. Matsuzaki M, Gallagher KP, Patritti J, et al. Effects of a calcium-entry blocker (diltiazem) on regional myocardial flow and function during exercise in conscious dogs. Circulation 1984; 69: 801-14
  9. Chiavarelli M, Chiavarelli R, Macchiarelli A, Carpi A, Marino B. Calcium entry blockers and cardioplegia: interaction between nifedipine, potassium, and hypothermia. Ann Thorac Surg 1986; 41: 535-41
  10. Yamamoto F, Mannig AS, Braimridge MV, Hearse DJ. Calcium antagonists and myocardial protection: diltiazem during cardioplegic arrest. Thorac Cardiovasc Surg 1983; 31: 369-73
  11. Janero DR, Burghardt B, Lopez R. Protection af cardiac membrane phospholipid aganist oxidative injury by calcium antagonists. Biochem Pharmacol 1988; 37: 4197-203
  12. Janero Dr, Burghardt B. Antiperoxidant effects of dihydropyridine calcium antagonists. Biochem Pharmacol 1989; 38: 4344-8
  13. Yagi K. A simple fluorometric assay for lipoperoxide in blood plasma. Biochem Med 1976; 15: 212-6
  14. Satoh K. Serum lipid peroxide in cerebrova